Gilead banking $1.3B for new deals
Free newsletter via e-mail
Tools
Analysts are bullish on Gilead Sciences, which recently sold $1.3 billion in debentures to fund new licensing deals and acquisitions. Gilead, which is receiving a substantial revenue stream from Roche for Tamiflu, has a deal to buy the remaining shares of Corus Pharma following Phase III data.
- read the Forbes report for more information
PLUS: Bristol-Myers Squibb and Gilead have filed for approval of a once-daily HIV treatment that combines Sustiva and Truvada. Report
More stories about Gilead Sciences Mergers and Acquisitions Phase III Tamiflu analysts Roche Bristol-Myers Squibb
SHARE
WITH: